BidaskClub downgraded shares of Merus (NASDAQ:MRUS) from a hold rating to a sell rating in a research report released on Thursday morning.

MRUS has been the subject of several other reports. Zacks Investment Research upgraded shares of Merus from a hold rating to a buy rating and set a $15.00 price objective for the company in a research report on Friday, March 15th. ValuEngine upgraded shares of Merus from a sell rating to a hold rating in a research report on Wednesday, March 6th. Finally, Citigroup lowered their price objective on shares of Merus from $18.00 to $16.00 and set a neutral rating for the company in a research report on Friday, March 15th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $21.67.

Shares of MRUS opened at $12.84 on Thursday. Merus has a one year low of $11.00 and a one year high of $26.74. The company has a market cap of $292.12 million, a price-to-earnings ratio of -2.99 and a beta of -0.12.

Merus (NASDAQ:MRUS) last announced its quarterly earnings data on Thursday, December 27th. The biotechnology company reported ($0.55) EPS for the quarter. Merus had a negative net margin of 140.49% and a negative return on equity of 55.96%. The firm had revenue of $7.57 million for the quarter, compared to analyst estimates of $4.25 million. Equities research analysts anticipate that Merus will post -2.18 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its stake in shares of Merus by 33.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 17,723 shares of the biotechnology company’s stock valued at $350,000 after purchasing an additional 4,476 shares during the period. Laurion Capital Management LP bought a new position in shares of Merus in the 3rd quarter valued at about $2,104,000. Aquilo Capital Management LLC grew its holdings in shares of Merus by 3.6% in the 3rd quarter. Aquilo Capital Management LLC now owns 1,295,713 shares of the biotechnology company’s stock valued at $25,577,000 after acquiring an additional 44,799 shares in the last quarter. Morgan Stanley grew its holdings in shares of Merus by 74.3% in the 3rd quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock valued at $1,415,000 after acquiring an additional 30,538 shares in the last quarter. Finally, Artal Group S.A. bought a new position in shares of Merus in the 4th quarter valued at about $2,886,000. 53.06% of the stock is currently owned by hedge funds and other institutional investors.

Merus Company Profile

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

Featured Story: Day Trading – Risk Worth the Reward?

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.